MIRXES-B(02629.HK) and Watson signed a memorandum of understanding to create a RNA-centric platform for prevention and precision healthcare.

Zhijun Finance APP News, MIRXES-B (02629.HK) announced that the company recently entered into a memorandum of understanding with Yunnan Watson Biotechnology Co., Ltd. (Watson). According to this, the contracting parties have agreed to leverage their complementary advantages to establish a strategic partnership centering on RNA-based prevention and precision medical platform, covering joint development, clinical trials and registration, as well as sales and distribution. The memorandum of understanding is valid for a period of two years from the date of signing (including that day).